430 related articles for article (PubMed ID: 17098336)
1. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
4. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
[TBL] [Abstract][Full Text] [Related]
5. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
6. Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus.
Xiao Y; Zeng Y; Schante C; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2020 Aug; 38(38):6007-6018. PubMed ID: 32741672
[TBL] [Abstract][Full Text] [Related]
7. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
8. The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.
Denzler KL; Schriewer J; Parker S; Werner C; Hartzler H; Hembrador E; Huynh T; Holechek S; Buller RM; Jacobs BL
Vaccine; 2011 Dec; 29(52):9691-6. PubMed ID: 21983358
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
[TBL] [Abstract][Full Text] [Related]
10. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
11. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.
Xiao Y; Zeng Y; Alexander E; Mehta S; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2013 Jan; 31(2):319-26. PubMed ID: 23153450
[TBL] [Abstract][Full Text] [Related]
12. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.
Reeman S; Gates AJ; Pulford DJ; Krieg A; Ulaeto DO
Viruses; 2017 Dec; 9(12):. PubMed ID: 29232844
[TBL] [Abstract][Full Text] [Related]
13. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
[TBL] [Abstract][Full Text] [Related]
14. The generation of CD8+ T-cell population specific for vaccinia virus epitope involved in the antiviral protection against ectromelia virus challenge.
Gierynska M; Szulc-Dabrowska L; Dzieciatkowski T; Golke A; Schollenberger A
Pathog Dis; 2015 Dec; 73(9):ftv088. PubMed ID: 26474845
[TBL] [Abstract][Full Text] [Related]
15. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
16. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
[TBL] [Abstract][Full Text] [Related]
17. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.
Aldaz-Carroll L; Xiao Y; Whitbeck JC; de Leon MP; Lou H; Kim M; Yu J; Reinherz EL; Isaacs SN; Eisenberg RJ; Cohen GH
J Virol; 2007 Aug; 81(15):8131-9. PubMed ID: 17522205
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.
Fogg CN; Americo JL; Lustig S; Huggins JW; Smith SK; Damon I; Resch W; Earl PL; Klinman DM; Moss B
Vaccine; 2007 Apr; 25(15):2787-99. PubMed ID: 17229505
[TBL] [Abstract][Full Text] [Related]
19. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
